Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.

doi:10.1016/S1474-4422(17)30056-X

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.

The Lancet. Neurology - 1 May 2017

Wile Daryl J, Agarwal Pankaj A, Schulzer Michael, Mak Edwin, Dinelle Katherine, Shahinfard Elham, Vafai Nasim, Hasegawa Kazuko, Zhang Jing, McKenzie Jessamyn, Neilson Nicole, Strongosky Audrey, Uitti Ryan J, Guttman Mark, Zabetian Cyrus P, Ding Yu-Shin, Adam Mike, Aasly Jan, Wszolek Zbigniew K, Farrer Matthew, Sossi Vesna, Stoessl A Jon

Abstract excerpt

BACKGROUND: People with Parkinson's disease can show premotor neurochemical changes in the dopaminergic and non-dopaminergic systems. Using PET, we assessed whether dopaminergic and serotonin transporter changes are similar in LRRK2 mutation carriers with Parkinson's disease and individuals with sporadic Parkinson's disease, and whether LRRK2 mutation carriers without motor symptoms show PET changes. METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross-Sectional Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dihydroxyphenylalanine

Share to Dopamine Plasma Membrane Transport Proteins

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Parkinson Disease

Share to Positron-Emission Tomography

Share to Radiopharmaceuticals

Share to Serotonin Plasma Membrane Transport Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 28336296
DOI: 10.1016/S1474-4422(17)30056-X
PMCID: PMC5477770

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.PMID 28336296Read ↗

The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.Semantic proximity Read ↗

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.Semantic proximity Read ↗

Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.Semantic proximity Read ↗

PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.Semantic proximity Read ↗

Cohort Profile: the Oxford Parkinson’s Disease Centre Discovery Cohort Magnetic Resonance Imaging sub-study (OPDC-MRI)Semantic proximity Read ↗

Neuroimaging Biomarkers in Parkinson's Disease: Current Applications and Future DirectionsSemantic proximity Read ↗

Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.Semantic proximity Read ↗

Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.Semantic proximity Read ↗

Disease progression in LRRK2 parkinsonism.Semantic proximity Read ↗

Molecular imaging in hereditary forms of parkinsonism.Semantic proximity Read ↗

LRRK2 -associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationSemantic proximity Read ↗

A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.